Fluorescent nanoprobes as a biomarker for increased vascular permeability: Implications in diagnosis and Treatment of Cancer and Inflammation

Bioconjugate Chemistry

Volumn 21, Issue 1, 2010, Pages 93-101

  Sandanaraj, Britto S ^a   Gremlich, Hans Ulrich ^a   Kneuer, Rainer ^a   Dawson, Janet ^a   Wacha, Stefan ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BIOAVAILABILITY; BLOOD VESSEL PERMEABILITY; CANCER DIAGNOSIS; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; FLUORESCENCE NANOPROBE; HALF LIFE TIME; HUMAN; HUMAN CELL; INFLAMMATION; MOUSE; NANOPROBE; NEOPLASM; NONHUMAN; TARGET CELL; TARGET ORGAN;

EID: 74949092512     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc900311h     Document Type: Article

References (57)

1. Severino, M. E., Dubose, R. F., and Patterson, S. D. (2006) A strategic view on the use of pharmacodynamic biomarkers in early clinical drug development. IDrugs. 9, 849-853.
2. Kuhlmann, J., and Wensing, G. (2006) The applications of biomarkers in early clinical drug development to improve decision-making processes. Curr. Clin. Pharmacol. 1, 185-191.
3. Bakhtiar, R. (2008) Biomarkers in drug discovery and development. J. Pharmacol. Toxicol. Methods 57, 85-91.
4. Frank, R., and Hargreaves, R. (2003) Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discovery 2, 566-580.
5. Colburn, W. A. (2003) Biomarkers in drug discovery and development: from target identification through drug marketing. J. Clin. Pharmacol. 43, 329-341.
6. Colburn, W. A. (2000) Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development. J. Clin. Pharmacol. 40, 1419-1427.
7. Hargreaves, R. J. (2008) The role of molecular imaging in drug discovery and development. Clin. Pharmacol. Ther. 83, 349-353.
8. Rudin, M. (2009) Noninvasive structural, functional, and molecular imaging in drug development. Curr. Opin. Chem. Biol. 13, 360-371.
9. Rudin, M. (2007) Imaging readouts as biomarkers or surrogate parameters for the assessment of therapeutic interventions. Eur. Radiol. 17, 2441-2457.
10. Rudin, M., and Weissleder, R. (2003) Molecular imaging in drug discovery and development. Nat. Rev. Drug Discovery 2, 123-131.
11. Maeda, H., Fang, J., Inutsuka, T., and Kitamoto, Y. (2003) Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 3, 319-328.
12. Andersson, S. E., Lexmuller, K., and Ekstrom, G. M. (1998) Physiological characterization of mBSA antigen induced arthritis in the rat. I. Vascular leakiness and pannus growth. J. Rheumatol. 25, 1772-1777.
13. Andersson, S. E., and Ekstrom, G. M. (1997) Changes in vascular porosity and joint blood flow during development of collagen induced arthritis in the rat. Modulation by indomethacin and L-NAME. J. Rheumatol. 24, 2188-2195.
14. Medarova, Z., Castillo, G., Dai, G., Bolotin, E., Bogdanov, A., and Moore, A. (2007) Noninvasive magnetic resonance imaging of microvascular changes in type 1 diabetes. Diabetes 56, 2677-2682.
15. De Paepe, M. E., Corriveau, M., Tannous, W. N., Seemayer, T. A., and Colle, E. (1992) Increased vascular permeability in pancreas of diabetic rats: detection with high resolution protein A-gold cytochemistry. Diabetologia 35, 1118-1124.
16. Muruganandham, M., Lupu, M., Dyke, J. P., Matei, C., Linn, M., Packman, K., Kolinsky, K., Higgins, B., and Koutcher, J. A. (2006) Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T. Mol. Cancer Ther. 5, 1950-1957.
17. Demsar, F., van Dijke, C. F., Kirk, B. A., Kapila, S., Peterfy, C. G., Roberts, T. P., Shames, D. M., Tomazic, S., Mann, J., and Brasch, R. C. (1996) Mapping abnormal synovial vascular permeability in temporomandibular joint arthritis in the rabbit using MRI. Br. J. Rheumatol. 35, 23-25, Suppl 3.
18. Kaplan, J. D., Trulock, E. P., Anderson, D. J., and Schuster, D. P. (1992) Pulmonary vascular permeability in interstitial lung disease. A positron emission tomographic study. Am. Rev. Respir. Dis. 145, 1495-1498.
19. Kruger, E. F., Puchalski, S. M., Pollard, R. E., Galuppo, L. D., Hornof, W. J., and Wisner, E. R. (2008) Measurement of equine laminar blood flow and vascular permeability by use of dynamic contrast-enhanced computed tomography. Am. J. Vet. Res. 69, 371-377.
20. Roberts, H. C., Roberts, T. P., Lee, T. Y., and Dillon, W. P. (2002) Dynamic, contrast-enhanced CT of human brain tumors: quantitative assessment of blood volume, blood flow, and microvascular permeability: report of two cases. Am. J. Neuroradiol. 23, 828-832.
21. Terada, T., Nambu, K., Hyotani, G., Miyamoto, K., Tsuura, M., Nakamura, Y., Nishiguchi, T., Itakura, T., Hayashi, S., and Komai, N. (1992) A method for quantitative measurement of cerebral vascular permeability using X-ray CT and iodinated contrast medium. Neuroradiology 34, 290-296.
22. Heppner, P., and Lindner, J. R. (2005) Contrast ultrasound assessment of angiogenesis by perfusion and molecular imaging. Expert Rev. Mol. Diagn. 5, 447-455.
23. Jaffer, F. A., Kim, D. E., Quinti, L., Tung, C. H., Aikawa, E., Pande, A. N., Kohler, R. H., Shi, G. P., Libby, P., and Weissleder, R. (2007) Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation 115, 2292-2298.
24. Pande, A. N., Kohler, R. H., Aikawa, E., Weissleder, R., and Jaffer, F. A. (2006) Detection of macrophage activity in atherosclerosis in vivo using multichannel, high-resolution laser scanning fluorescence microscopy. J. Biomed. Opt. 11, 021009.
25. Wunder, A., Tung, C. H., Muller-Ladner, U., Weissleder, R., and Mahmood, U. (2004) In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. Arthritis Rheum. 50, 2459-2465.
26. Weissleder, R., and Ntziachristos, V. (2003) Shedding light onto live molecular targets. Nat. Med. 9, 123-128.
27. Petrovsky, A., Schellenberger, E., Josephson, L., Weissleder, R., and Bogdanov, A., Jr. (2003) Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res. 63, 1936-1942.
28. Weissleder, R., Tung, C. H., Mahmood, U., and Bogdanov, A., Jr. (1999) In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat. Biotechnol. 17, 375-378.
29. Hansch, A., Frey, O., Hilger, I., Sauner, D., Haas, M., Schmidt, D., Kurrat, C., Gajda, M., Malich, A., Brauer, R., and Kaiser, W. A. (2004) Diagnosis of arthritis using near-infrared fluorochrome Cy5.5. Invest. Radiol. 39, 626-632.
30. Hickson, J. (2009) In vivo optical imaging: preclinical applications and considerations. Urol. Oncol. 27, 295-297.
31. Wong, D. F. (2008) Imaging in drug discovery, preclinical, and early clinical development. J. Nucl. Med. 49, 26N-28N.
32. Kiesslich, R., Gossner, L., Goetz, M., Dahlmann, A., Vieth, M., Stolte, M., Hoffman, A., Jung, M., Nafe, B., Galle, P. R., and Neurath, M. F. (2006) In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy. Clin. Gastroenterol. Hepatol. 4, 979-987.
33. Kiesslich, R., Burg, J., Vieth, M., Gnaendiger, J., Enders, M., Delaney, P., Polglase, A., McLaren, W., Janell, D., Thomas, S., Nafe, B., Galle, P. R., and Neurath, M. F. (2004) Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology 127, 706-713.
34. Torchilin, V. P. (2005) Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discovery 4, 145-160.
35. Zhu, L., Zheng, Y., von Kerczek, C. H., Topoleski, L. D., and Flower, R. W. (2006) Feasibility of extracting velocity distribution in choriocapillaris in human eyes from ICG dye angiograms. J. Biomech. Eng. 128, 203-209.
36. Ishigami, Y., Masuzawa, M., Miyoshi, E., Kato, M., Tamura, K., Kanda, M., Awazu, K., Taniguchi, K., Kurita, M., and Hayashi, N. (1993) Clinical applications of ICG Finger Monitor in patients with liver disease. J. Hepatol. 19, 232-240.
37. Klibanov, A. L., Maruyama, K., Torchilin, V. P., and Huang, L. (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268, 235-237.
38. Maeda, H., Sawa, T., and Konno, T. (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Controlled Release 74, 47-61.
39. Harasym, T. O., Tardi, P., Longman, S. A., Ansell, S. M., Bally, M. B., Cullis, P. R., and Choi, L. S. (1995) Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. Bioconjugate Chem. 6, 187-194.
40. Jain, R. K., Schlenger, K., Hockel, M., and Yuan, F. (1997) Quantitative angiogenesis assays: progress and problems. Nat. Med. 3, 1203-1208.
41. Brown, E. B., Campbell, R. B., Tsuzuki, Y., Xu, L., Carmeliet, P., Fukumura, D., and Jain, R. K. (2001) In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat. Med. 7, 864-868.
42. Gratton, S. E., Napier, M. E., Ropp, P. A., Tian, S., and DeSimone, J. M. (2008) Microfabricated particles for engineered drug therapies: elucidation into the mechanisms of cellular internalization of PRINT particles. Pharm. Res. 25, 2845-2852.
43. Gratton, S. E., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., and DeSimone, J. M. (2008) The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. U.S.A. 105, 11613-11618.
44. Levick, J. R. (1981) Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum. 24, 1550-1560.
45. Kushner, I., and Somerville, J. A. (1971) Permeability of human synovial membrane to plasma proteins. Relationship to molecular size and inflammation. Arthritis Rheum. 14, 560-570.
46. Yamaki, K., Uchida, H., Li, X., Yanagisawa, R., Takano, H., Hayashi, H., Mori, Y., and Yoshino, S. (2005) Effect of varying types of anti-arthritic drugs on Th1 and Th2 immune responses in mice. Int. J. Immunopathol. Pharmacol. 18, 133-144.
47. Takeshita, M., Sugita, T., and Takata, I. (1997) Pathological evaluation of effect of anti-rheumatic drugs on type II collagen-induced arthritis in Lewis rats. Exp. Anim. 46, 165-169.
48. Ueno, M., Imaizumi, K., Sugita, T., Takata, I., and Takeshita, M. (1995) Effect of a novel anti-rheumatic drug, TA-383, on type II collagen-induced arthritis. Int. J. Immunopharmacol. 17, 597-603.
49. Hansch, A., Frey, O., Sauner, D., Hilger, I., Haas, M., Malich, A., Brauer, R., and Kaiser, W. A. (2004) In vivo imaging of experimental arthritis with near-infrared fluorescence. Arthritis Rheum. 50, 961-967.
50. Desmettre, T., Devoisselle, J. M., and Mordon, S. (2000) Fluorescence properties and metabolic features of indocyanine green (ICG) as related to angiography. Surv. Ophthalmol. 45, 15-27.
51. Mordon, S., Devoisselle, J. M., Soulie-Begu, S., and Desmettre, T. (1998) Indocyanine green: physicochemical factors affecting its fluorescence in vivo. Microvasc. Res. 55, 146-152.
52. Hansch, A., Sauner, D., Hilger, I., Frey, O., Haas, M., Malich, A., Brauer, R., and Kaiser, W. A. (2003) Noninvasive diagnosis of arthritis by autofluorescence. Invest. Radiol. 38, 578-583.
53. Naumov, G. N., Folkman, J., and Straume, O. (2009) Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin. Exp. Metastasis 26, 51-60.
54. Naumov, G. N., Folkman, J., Straume, O., and Akslen, L. A. (2008) Tumor-vascular interactions and tumor dormancy. APMIS 116, 569-585.
55. Naumov, G. N., Akslen, L. A., and Folkman, J. (2006) Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5, 1779-1787.
56. Folkman, J. (2002) Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15-18.
57. Jain, R. K. (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.